

IN THE CLAIMS:

1. (Canceled).

2. (Previously Amended)

The pharmaceutical composition according to claim

~~6~~, wherein the neuropathic pain is induced by diabetes or compression of nerves.

3. (Previously Amended)

The pharmaceutical composition according to claim

~~2~~, wherein the neuropathic pain is induced by diabetes.

4. (Previously Amended)

The pharmaceutical composition according to claim

~~6~~, wherein the systemic administration method is oral administration.

5. (Canceled).

~~6~~. (Previously Amended)

A pharmaceutical composition for use in treating

neuropathic pain, which is administered by a systemic method of administration and which comprises a compound having mGluR1 antagonistic activity, wherein the compound having mGluR1 antagonism is a compound selected from 6-amino-N-cyclohexyl-N,3-dimethylthiazolo[3,2-a]benzoimidazole-2-carboxamide dihydrochloride and (+)-(1R,2S)-6-amino-N-methyl-N-(2-methylcyclohexyl)thiazolo[3,2-a]benzoimidazole-2-carboxamide dihydrochloride.

7-11 (Canceled).